Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer
Biomolecules · 06.01.2026 · 16 (1) · 93
DOI: 10.3390/biom16010093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 06.01.2026. Verfasst von Aynura Mammadova und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Breast Neoplasms, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Susan G. Komen Breast Cancer Foundation, Winship Cancer Institute, Susan G. Komen for the Cure.
Abstract (Originalsprache)
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have transformed the treatment landscape for estrogen receptor-positive (ER+) breast cancer, yet resistance remains a major clinical challenge. Although CDK4/6i induce G1 arrest and therapy-induced senescence (TIS), the exact nature of this senescent state and its contribution to resistance are not well understood. To explore this, we developed palbociclib- (2PR, 9PR, TPR) and abemaciclib- (2AR, 9AR, TAR) resistant ER+ breast cancer sublines through prolonged drug exposure over six months. Resistant cells demonstrated distinct phenotypic alterations, including cellular senescence, reduced mitochondrial membrane potential, and impaired glycolytic activity. Cytokine profiling and enzyme-linked immunosorbent assay (ELISA) validation revealed a non-canonical senescence-associated secretory phenotype (SASP) characterized by elevated growth/differentiation factor 15 (GDF-15) and serpin E1 (plasminogen activator inhibitor-1, PAI-1) and absence of classical pro-inflammatory interleukins, including IL-1α and IL-6. IL-8 levels were significantly elevated, but no association with epithelial–mesenchymal transition (EMT) was observed. Resistant cells preserved their epithelial morphology, showed no upregulation of EMT markers, and lacked aldehyde dehydrogenase 1-positive (ALDH1+) stem-like populations. Additionally, Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES) was strongly upregulated in palbociclib-resistant cells. Together, these findings identify a distinct, non-canonical senescence phenotype associated with CDK4/6i resistance and may provide a foundation for identifying new vulnerabilities in resistant ER+ breast cancers through targeting SASP-related signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Sunil S Badve, Yesim Gökmen-Polar
Förderung
- Susan G. Komen Breast Cancer Foundation
- Winship Cancer Institute
- Susan G. Komen for the Cure
- Winship Invest$ Winter 2022 grant
- Emory University
Zitieren
APA
Mammadova, A., Gu, Y., Ruan, L., Badve, S. S., & Gökmen-Polar, Y. (2026). Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer. Biomolecules, 16(1), 93. https://doi.org/10.3390/biom16010093
Vancouver
Mammadova A, Gu Y, Ruan L, Badve SS, Gökmen-Polar Y. Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer. Biomolecules. 2026;16(1):93. doi:10.3390/biom16010093
BibTeX
@article{Mammadova2026,
author = {Mammadova, Aynura and Gu, Yuan and Ruan, Ling and Badve, Sunil S and Gökmen-Polar, Yesim},
title = {Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast Cancer},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {1},
pages = {93},
doi = {10.3390/biom16010093}
}
EUVIMED